CN Patent

CN108495629A — 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法

Assigned to Ipsen Biopharm Ltd · Expires 2018-09-04 · 8y expired

What this patent protects

包括脂质体伊立替康、奥沙利铂和5‑氟尿嘧啶的组合疗法方案可用于治疗胰腺癌，包括治疗诊断患有先前未治疗的转移性胰腺腺癌的患者。所述组合疗法可包括每两周一次施用脂质体伊立替康、奥沙利铂、亚叶酸和5‑氟尿嘧啶。

USPTO Abstract

包括脂质体伊立替康、奥沙利铂和5‑氟尿嘧啶的组合疗法方案可用于治疗胰腺癌，包括治疗诊断患有先前未治疗的转移性胰腺腺癌的患者。所述组合疗法可包括每两周一次施用脂质体伊立替康、奥沙利铂、亚叶酸和5‑氟尿嘧啶。

Drugs covered by this patent

Patent Metadata

Patent number
CN108495629A
Jurisdiction
CN
Classification
—
Expires
2018-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Biopharm Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.